Shehnaaz Suliman
CIK 1713070 · President and COO · last filed 2026-09-24
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ALEC price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
60 LEVERONI COURT
NOVATO, CA 94949
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TXG | Director | 23,792 | $57.52 | $1.37M | -$791.9K | 11 | 2026-09-24 |
| RARE | Director | 27,951 | $17.18 | $480.2K | -$144.2K | 9 | 2026-05-18 |
| ALEC | President and COO | 102,598 | $2.32 | $237.9K | -$6.65M | 5 | 2021-12-14 |
| Theravance Biopharma, Inc. (TBPH) Delisted | SVP, Corp Dev & Strategy | 97,198 | $17.03 | $1.66M | $0 | 4 | 2019-02-22 |
Recent Filings · Page 2 of 4
33 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-05-19 | RARE | Grant (A) | +5,740 | $0 | EDGAR |
| 2024-06-20 | RARE | Grant (A) | +5,345 | $0 | EDGAR |
| 2024-06-13 | TXG | Grant (A) | +8,649 | $0 | EDGAR |
| 2023-06-16 | TXG | Grant (A) | +1,865 | $0 | EDGAR |
| 2023-06-09 | RARE | Grant (A) | +3,860 | $0 | EDGAR |
| 2022-06-28 | RARE | Grant (A) | +3,300 | $0 | EDGAR |
| 2022-06-17 | TXG | Grant (A) | +2,120 | $0 | EDGAR |
| 2021-12-14 | ALEC | Mixed | — | -$640.8K | EDGAR |
| 2021-12-10 | ALEC | Mixed | — | -$1.22M | EDGAR |
| 2021-06-28 | RARE | Grant (A) | +2,145 | $0 | EDGAR |
10b5-1: the filer ticked the box for trades made under a Rule 10b5-1 trading plan, which sets the sales (or buys) in advance, so they say less about the insider's view at the time than a discretionary trade. The plan's adoption date is shown when the filing's footnotes give it.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment, and an amended or cancelled notice is not listed. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes. Someone who is no longer an officer or director (or never was) files no Form 4, so for them a sale shows up only on a later notice, which lists the seller's sales from the 3 months before it. "No sale on file" means neither record shows one; a dash in Net $ means the value filed on the notice doesn't fit the stock's price (likely a typo).